MacroGenics Q1 2025 Update: Revenue Streams Detailed
Ticker: MGNX · Form: 10-Q · Filed: May 13, 2025 · CIK: 1125345
| Field | Detail |
|---|---|
| Company | Macrogenics INC (MGNX) |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, revenue, pharmaceutical
TL;DR
MGNX Q1 2025: Revenue breakdown from collaborations, products, and manufacturing. Balance sheet details from end of 2024.
AI Summary
MacroGenics Inc. reported its first quarter 2025 results for the period ending March 31, 2025. The company's financial filings indicate revenue from collaborative agreements and product sales, alongside contract manufacturing and government contracts. Specific financial figures for these revenue streams and balance sheet items like common stock and retained earnings as of December 31, 2024, are detailed within the report.
Why It Matters
This filing provides investors with a snapshot of MacroGenics' financial performance and revenue sources for the first quarter of 2025, crucial for understanding the company's operational health.
Risk Assessment
Risk Level: medium — The company operates in the pharmaceutical sector, which is inherently subject to regulatory, clinical trial, and market risks.
Key Numbers
- 2025 Q1 — Reporting Period (First quarter of 2025)
- 2024-12-31 — Balance Sheet Date (End of fiscal year 2024)
Key Players & Entities
- MACROGENICS INC (company) — Filer
- 20250331 (date) — Reporting Period End Date
- 20250513 (date) — Filing Date
- 2024-12-31 (date) — Prior Period Balance Sheet Date
FAQ
What were MacroGenics' total revenues from collaborative agreements for the first quarter of 2025?
The filing indicates revenue from collaborative agreements for the period January 1, 2025, to March 31, 2025, but the specific dollar amount is not provided in this excerpt.
How did product revenue in Q1 2025 compare to Q1 2024 for MacroGenics?
The filing shows product revenue for both Q1 2025 and Q1 2024, but the specific dollar amounts are not detailed in this section.
What is the company's fiscal year end?
MacroGenics Inc.'s fiscal year ends on December 31.
What is the SIC code for MacroGenics Inc.?
The Standard Industrial Classification code for MacroGenics Inc. is 2834, Pharmaceutical Preparations.
What are the key balance sheet components reported as of December 31, 2024?
Key balance sheet components reported as of December 31, 2024, include Common Stock, Additional Paid-In Capital, Retained Earnings, and Accumulated Other Comprehensive Income (AOCI).
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding MACROGENICS INC (MGNX).